Skip to main content

Table 4 Prevalence of anaemia according to selected risk factors among HIV infected pregnant women receiving co-trimoxazole prophylaxis (N = 420)

From: Prevalence of malaria and anaemia among HIV infected pregnant women receiving co-trimoxazole prophylaxis in Tanzania: a cross sectional study in Kinondoni Municipality

Univariate analysis Multivariate analysis
Characteristics n Prevalence of anaemia n (%) P-value AOR 95% CI P-value
Malaria infection       
Yes 19 18 (94.7)   10.363 1.329-80.798 0.026
No (reference) 401 209 (52.1) 0.0001a 1   
History of malaria illness       
Yes 107 76 (71)   1.746 1.005-3.033 0.048
No (reference) 313 151 (48.2) 0.0001a 1   
WHO clinical stage       
Stage I (reference) 338 165 (48.8)   1   
Stage II 43 32 (74.4)   3.076 1.458-6.491 0.003
Stage III-IV 37 30 (76.9) 0.0001a 2.653 1.184-5.945 0.018
CD4 count (cells/μL)*       
≥500 104 48 (46.2)   -   
350-499 85 45 (52.9)   -   
200-349 96 62 (64.6)     
<200 59 42 (71.2) 0.005a -   
Pregnancy trimester       
1st trimester 20 9 (45)   -   
2nd trimester 206 107 (51.9)   -   
3rd trimester 194 111 (57.2) 0.404a -   
Gravidity       
Primigravidae 139 72 (51.8)   -   
Secundigravidae 148 83 (56.1)   -   
Multigravidae 133 72 (54.1) 0.767a -   
ITN use       
Yes 380 201 (52.9)   -   
No 40 26 (65) 0.144a -   
ART category       
ARV Prophylaxis 288 146 (50.7)   -   
Life-long ART 132 81 (61.4) 0.142a -   
Duration of AZT use (months)       
<3 162 93 (57.4)   -   
3-5.9 168 92 (54.8)     
≥6 90 42 (46.7) 0.253a -   
Iron supplements       
Yes 338 185 (54.7)   -   
No 82 42 (51.2) 0.567a -   
Use of de-worming drug       
Yes 327 171 (52.3)   -   
No 93 56 (60.2) 0.176a -   
Adherence to co-trimoxazole       
Good (reference) 208 92 (44.2)   1   
Average 80 47 (58.8)   1.478 0.848-2.578 0.168
Poor 132 88(66.7) 0.0001a 1.752 1.03-2.979 0.039
  1. aCalculated by Pearson Chi Square, *Results of CD4 Count were available for only 344 subjects out of 420 (81.9%).